Israel’s Silexion reported here in April that its SIL-204 reduced pancreatic tumors. Latest studies show it also works on lung cancer. Its silencing of KRAS protein mutations achieved unprecedented inhibition rates of up to 97% in pancreatic cancer cells and nearly 90% in colorectal cancer cells.
Promising treatment for cancer
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.